Hospital

Investigators found that electronic letter reminders were most effective for older individuals, those who were unvaccinated in the preceding season, those with cardiovascular disease, and those with diabetes.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

Utilizing data from the CHAMPION MG trial, investigators found that many patients had responded to ravulizumab and returned to daily activities within 2 weeks.

Historically, colchicine has been used primarily in the management of gout; however, in 2023, the FDA approved Lodoco, a newly marketed colchicine product, for the management of cardiovascular disease.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

Findings highlight the need for health care providers to continue to educate patients on the risk of scurvy, ensuring proper vitamin C intake.

Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.

Despite self-reported improvements in cognitive function, neuropsychological tests showed little differences between 2 patient groups.

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

Benefits include reducing serious health consequences, such as hospitalization and death, as well as the economic burden on health systems due to influenza infection.

Higher doses of β-blockers are associated with better clinical outcomes in patient with heart failure.

Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.

Despite suggestions to the contrary in previously conducted small clinical trials, montelukast did not provide benefit in patients with COVID-19 symptoms.

Endometriosis is a systemic disease that can affect multiple parts of the body, not just the pelvis.

New recommendations from the American Stroke Association (ASA) emphasize the importance of healthy lifestyle habits and addressing health equity to reduce stroke risk.

In April 2024, the FDA approved ustekinumab-aekn as a subcutaneous injection for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

There are gonadotoxic risks of chemotherapy, radiation, and surgery that are important to discuss with patients.

Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.

Therapy-related complications, in addition to financial obstacles, can complicate myasthenia gravis treatment.

The implementation of accountable care organizations (ACOs) also worsened disparities in any emergency department or hospital use for Medicaid-insured children with asthma.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.

The connection of F proteins could help destabilize the virus prior to infection of the next host.

The results emphasize the need for pharmacists and health care providers to further educate patients about receiving recommended immunizations.

The additions include Dextrose 70% intravenous (IV) solution, Lactated Ringers IV Solution, and Peritoneal Dialysis Solution, which were affected by Hurricane Helene.

Recognizing repeat dosing efforts is important to improving outcomes in patients with Guillain-Barré syndrome who do not respond to IVIG.

Research funding that aims to understand impacts of systemic racism on pediatric asthma should include plans to undo policies that maintain inequities created by systemic racism.

The researchers observe that the combination treatment results in higher serum levels compared with ezetimibe alone.

HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.

The gold standard of testing for food allergies is an oral food challenge test where patients consume the allergen, such as peanut extract, under supervision.